Michael A. Jakupec

16.1k citations

228 papers · 14.1k indexed · 5 hit papers · h-index 62

Co-authors: Bernhard K. Keppler M. Galanski Christian G. Hartinger Vladimir B. Arion Walter Berger Petra Heffeter Haralabos Zorbas Stefanie Zorbas‐Seifried
Topics: Metal complexes synthesis and properties (174 papers)Ferrocene Chemistry and Applications (75 papers)Lanthanide and Transition Metal Complexes (38 papers)
Cited by: Oncology Organic Chemistry Inorganic Chemistry
Journals: Angewandte Chemie International Edition Journal of Clinical Oncology Cancer Research
Partner nations: Austria Germany Slovakia

In The Last Decade

Michael A. Jakupec

226 papers receiving 13.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)

2006 860 citations Michael A. Jakupec, Bernhard K. Keppler et al. profile →
Antitumour metal compounds: more than theme and variations

2007 761 citations Michael A. Jakupec, M. Galanski et al. Dalton Transactions profile →
KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

2008 732 citations Michael A. Jakupec, Walter Berger et al. profile →
Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches

2005 631 citations M. Galanski, Michael A. Jakupec et al. Current Medicinal Chemistry profile →
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application

2014 583 citations Petra Heffeter, Michael A. Jakupec et al. Chemical Science profile →

Peers

Countries citing papers authored by Michael A. Jakupec

Since Specialization

Citations

This map shows the geographic impact of Michael A. Jakupec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Jakupec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Jakupec more than expected).

Fields of papers citing papers by Michael A. Jakupec

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Jakupec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Jakupec. The network helps show where Michael A. Jakupec may publish in the future.

Co-authorship network of co-authors of Michael A. Jakupec

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Jakupec. A scholar is included among the top collaborators of Michael A. Jakupec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Jakupec. Michael A. Jakupec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Selectivity for TP53 signalling drives the mode of action of a highly potent N , O , O -tridentate naphthoquinone-based organo-ruthenium anticancer drug candidate 2025 ·Chemical Science ·(unknown),(unknown),(unknown),Dina Baier,Michaela Hejl,(unknown),(unknown),(unknown),Thomas Mohr,Anton A. Legin,Michael A. Jakupec,Andrea Bileck,Christopher Gerner,Gunda Koellensperger,Petra Heffeter,Walter Berger,Bernhard K. Keppler,Wolfgang Kandioller,Samuel M. Meier	0
2	Flavan-Benzofurans from Artocarpus lacucha: Their Intracellular Antioxidant Activity and Molecular Docking to Glutathione Reductase 2024 ·ACS Omega ·(unknown),(unknown),Michael A. Jakupec,(unknown),(unknown),Lothar Brecker,Johann Schinnerl,(unknown),Wanchai Pluempanupat	0
3	Investigating the anticancer potential of 4-phenylthiazole derived Ru(ii) and Os(ii) metalacycles 2024 ·Dalton Transactions ·(unknown),(unknown),(unknown),Orsolya Dömötör,Michaela Hejl,Alexander Roller,Klaudia Cseh,Anton A. Legin,Michael A. Jakupec,Giampaolo Barone,Alessio Terenzi,Bernhard K. Keppler,Wolfgang Kandioller	6
4	Combination of Drug Delivery Properties of PAMAM Dendrimers and Cytotoxicity of Platinum(IV) Complexes—A More Selective Anticancer Treatment? 2023 ·Pharmaceutics ·(unknown),Michaela Hejl,(unknown),Michael A. Jakupec,Walter Berger,M. Galanski,Bernhard K. Keppler	4
5	Not the usual suspect – an unexpected organometallic product during the synthesis of cytotoxic platinum(ii) complexes 2023 ·Dalton Transactions ·Thomas Maier,(unknown),(unknown),Michaela Hejl,Klaudia Cseh,Sebastian Mai,Michael A. Jakupec,M. Galanski,Bernhard K. Keppler	1
6	Anticancer Tungstenocenes with a Diverse Set of (O,O–), (O,S–) and (O,N–) Chelates—A Detailed Biological Study Using an Improved Evaluation via 3D Spheroid Models 2023 ·Pharmaceutics ·Klaudia Cseh,(unknown),(unknown),(unknown),Andreas Schweikert,Alexander Roller,Michaela Hejl,(unknown),Gunda Koellensperger,Michael A. Jakupec,Wolfgang Kandioller,(unknown),Bernhard K. Keppler	1
7	Highly Cytotoxic Molybdenocenes with Strong Metabolic Effects Inhibit Tumour Growth in Mice 2022 ·Chemistry - A European Journal ·(unknown),Klaudia Cseh,Michaela Hejl,(unknown),Benjamin Neuditschko,Samuel M. Meier,Lukas Janker,Andrea Bileck,(unknown),(unknown),(unknown),(unknown),Gunda Köllensperger,Christopher Gerner,Walter Berger,Michael A. Jakupec,(unknown),Bernhard K. Keppler	3
8	Tridentate 3-Substituted Naphthoquinone Ruthenium Arene Complexes: Synthesis, Characterization, Aqueous Behavior, and Theoretical and Biological Studies 2021 ·Inorganic Chemistry ·(unknown),Julia Westermayr,Klaudia Cseh,(unknown),(unknown),(unknown),(unknown),(unknown),Michaela Hejl,Michael A. Jakupec,Philipp Marquetand,Wolfgang Kandioller	15
9	Plecstatin-1 induces an immunogenic cell death signature in colorectal tumour spheroids 2020 ·Metallomics ·(unknown),Samuel M. Meier,Klaudia Cseh,Sarah Theiner,(unknown),Andreas Schweikert,Michael A. Jakupec,Gunda Koellensperger,Andreas Wernitznig,Wolfgang Sommergruber,Bernhard K. Keppler	38
10	Synthesis, Modification, and Biological Evaluation of a Library of Novel Water‐Soluble Thiopyridone‐Based Organometallic Complexes and Their Unexpected (Biological) Behavior 2020 ·Chemistry - A European Journal ·(unknown),(unknown),(unknown),(unknown),Michaela Hejl,(unknown),Anton A. Legin,Andreas Schweikert,(unknown),Alexander Roller,Gunda Koellensperger,Michael A. Jakupec,Wolfgang Kandioller,Bernhard K. Keppler	13
11	IntroducingN-,P-, andS-donor leaving groups: an investigation of the chemical and biological properties of ruthenium, rhodium and iridium thiopyridone piano stool complexes 2020 ·Dalton Transactions ·(unknown),(unknown),(unknown),(unknown),(unknown),Michaela Hejl,Michael A. Jakupec,Sarah Theiner,Gunda Koellensperger,Wolfgang Kandioller,Bernhard K. Keppler	12
12	The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects 2019 ·Chemistry - A European Journal ·(unknown),Klaudia Cseh,Alexander Roller,Michaela Hejl,Petra Heffeter,Walter Berger,Michael A. Jakupec,Wolfgang Kandioller,(unknown),Bernhard K. Keppler	10
13	Naphthoquinones of natural origin: Aqueous chemistry and coordination to half-sandwich organometallic cations 2019 ·Journal of Organometallic Chemistry ·(unknown),(unknown),(unknown),Alexander Roller,(unknown),Michaela Hejl,Michael A. Jakupec,Bernhard K. Keppler,Wolfgang Kandioller,Éva A. Enyedy	7
14	First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro 2019 ·Metallomics ·(unknown),Konstantinos Kiakos,Giorgia Del Favero,Nathalie Harrer,Herwig Machat,Annika Oßwald,Michael A. Jakupec,Andreas Wernitznig,Wolfgang Sommergruber,Bernhard K. Keppler	115
15	N- and S-donor leaving groups in triazole-based ruthena(ii)cycles: potent anticancer activity, selective activation, and mode of action studies 2018 ·Dalton Transactions ·(unknown),Michaela Hejl,Matthias H. M. Klose,Alexander Roller,Michael A. Jakupec,Wolfgang Kandioller,Bernhard K. Keppler	19
16	Comparative equilibrium and structural studies of new pentamethylcyclopentadienyl rhodium complexes bearing (O,N) donor bidentate ligands 2017 ·Journal of Organometallic Chemistry ·Orsolya Dömötör,(unknown),(unknown),Alexander Roller,Michaela Hejl,Michael A. Jakupec,Bernhard K. Keppler,Wolfgang Kandioller,Éva A. Enyedy	11
17	Amidoxime platinum(ii) complexes: pH-dependent highly selective generation and cytotoxic activity 2017 ·New Journal of Chemistry ·Dmitrii S. Bolotin,Marina Ya. Demakova,Anton A. Legin,Vitalii V. Suslonov,Alexey A. Nazarov,Michael A. Jakupec,Bernhard K. Keppler,Vadim Yu. Kukushkin	10
18	Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates 2016 ·Inorganic Chemistry ·(unknown),(unknown),Michaela Hejl,Alexander Roller,Matthias H. M. Klose,Michael A. Jakupec,Wolfgang Kandioller,Bernhard K. Keppler	55
19	Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approachesbreakdown → 2005 ·Current Medicinal Chemistry ·M. Galanski,Michael A. Jakupec,Bernhard K. Keppler	631
20	Recent Developments in the Field of Tumor-Inhibiting Metal Complexes 2003 ·Current Pharmaceutical Design ·M. Galanski,V.B. Arion,Michael A. Jakupec,Bernhard K. Keppler	452

About Michael A. Jakupec

Michael A. Jakupec is a scholar working on Oncology, Organic Chemistry and Toxicology, having authored 228 papers that have together received 14.1k indexed citations. Recurring topics across this work include Metal complexes synthesis and properties (174 papers), Ferrocene Chemistry and Applications (75 papers) and Lanthanide and Transition Metal Complexes (38 papers). The work is most often cited by research in Oncology (10.5k citations), Organic Chemistry (8.7k citations) and Inorganic Chemistry (2.0k citations). Michael A. Jakupec has collaborated with scholars based in Austria, Germany and Slovakia. Frequent co-authors include Bernhard K. Keppler, M. Galanski, Christian G. Hartinger, Vladimir B. Arion, Walter Berger, Petra Heffeter, Haralabos Zorbas, Stefanie Zorbas‐Seifried, Christian R. Kowol and Alexander Roller. Their work appears in journals such as Angewandte Chemie International Edition, Journal of Clinical Oncology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact